Navigation Links
New Blood Thinner May Work Without Bleeding Risk

LEXINGTON, Ky. − When studying a new blood thinner, one of the first signs the drug is working is seeing a slight increase in minor bleeding—nose bleeds and bruising,// an inconvenient side effect of preventing the blood clots that are the leading cause of heart attack and stroke. While potentially life-saving, the drugs can also pose a risk of major bleeding in some patients, requiring frequent monitoring of blood levels.

So when he didn’t see any significant increase in those typical bleeding events when studying a new blood thinner last year, UK College of Medicine cardiovascular chief David Moliterno was surprised when, at the close of the study in September, the results showed promise of significantly reducing the risk of heart attack and death with no statistical increase in major and minor bleeding events.

The drug, called a thrombin-receptor antagonist, or TRA, works in a unique way to prevent clotting by breaking down the communication between cells and proteins involved in forming clots. TRA, which is manufactured by Schering-Plough Corporation, was given in addition to established anti-clotting drugs to 1,030 patients undergoing cardiac catheterization and related intervention at 77 sites in six countries (including the United States, Canada, Italy, Belgium, Netherlands and Germany). The University of Kentucky enrolled 32 patients between August 2005 and September 2006. Patient follow-up was completed in January 2007.

“We were surprised by the extent of benefit,” Moliterno said. “These results are so noteworthy because the study demonstrated that this first-in-class TRA did not increase bleeding at all in a group of patients that is certainly at risk. And honestly, therefore, we did not expect to see a large benefit. While further study is required, we observed a 46 percent lowering in serious cardiovascular events, mainly a reduction in heart attacks. This represents an early and strong efficacy signal for this novel antiplatelet compound. This is encouraging, particularly in light of the fact that this patient population requires advanced therapies and is difficult to treat.”

Moliterno presented the study findings to thousands of cardiologists Saturday at the opening of the American College of Cardiology’s annual scientific sessions, taking place this year in New Orleans. Moliterno and other UK Linda and Jack Gill Heart Institute cardiologists will be giving a record 26 presentations, including 10 original research study releases, at the week-long ACC scientific sessions and Innovation in Intervention: i2 Summit 2007.

Source-Bio-Bio TechnologySRM
'"/>




Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Blood clots likely in long travel
4. Hemochromatosis Patients Blood is Safe
5. Blood transfusions beneficial after heart attacks
6. Blood Pressure Drug may slow wasting in burn victims
7. Levels Of Blood Proteins May Help Heart Disease Care
8. Blood test may identify ovarian cancer
9. A Blood test for suicide risk?
10. Blood Pressure Drugs maintain muscle strength
11. Blood test diagnoses heart failure in short time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... ... March 30, 2017 , ... ... educational offerings of corporate finance programs to address the increasingly complex educational needs ... executives increase their knowledge of sophisticated corporate finance and will increase their ability ...
(Date:3/30/2017)... , ... March 30, 2017 , ... ... submitted a letter to President Trump expressing their support for an independent Vaccine ... two Ph.D. scientists and one medical journalist, will hold a press conference at ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Full Contact ... founder of Pet Protect Law that assists dog owners in creating legally-enforceable ... new owners in taking the natural next step to protect their new companion. Says ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested ... Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. The FASTBRACES ... orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES system could ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Experts in the field in alcohol ... Soberlink Systems  as a model for recovery through ... early 2017, concluded that remote blood alcohol monitoring ... recovery." The findings of the expert ... detail a range of variables that are commonplace ...
(Date:3/29/2017)... March 29, 2017  Glenmark Pharmaceuticals, a global ... 301, an investigational fixed-dose combination of mometasone furoate ... twice-daily as a nasal spray being studied for ... are from a recently completed Phase 3 trial ... combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global lifestyle drugs market to grow at a ... report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: